Ipilimumab-induced granulomatous disease occurring simultaneously with disease progression in a patient with metastatic melanoma

Anis Toumeh, Ramen Sakhi, Sarthi Shah, Sri Krishna Chaitanya Arudra, Luis E. De Las Casas, Roland T. Skeel

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Malignant melanoma is the most aggressive cutaneous malignancy with dismal prognosis in the advanced setting. The food and drug administration approval of ipilimumab, the monoclonal antibody against cytotoxic T-lymphocyte antigen 4, has significantly changed treatment strategies for this disease. However, the spectrum of immune-related adverse events secondary to ipilimumab therapy is a growing area of research, and clinical observations of rare immune events as a result of such therapies continue to be reported since the approval. The co-occurrence of disease progression along with an immune-related adverse event is extremely rare. We here present the first case, to our knowledge, of diffuse nonnecrotizing granulomatous lymphadenopathy occurring simultaneously with disease progression in a patient with metastatic melanoma after receiving the second dose of ipilimumab.

Original languageEnglish (US)
Pages (from-to)e1068-e1071
JournalAmerican Journal of Therapeutics
Volume23
Issue number4
DOIs
StatePublished - Aug 1 2016
Externally publishedYes

Keywords

  • Granuloma
  • Ipilimumab
  • Metastatic melanoma
  • Nonnecrotizing

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Ipilimumab-induced granulomatous disease occurring simultaneously with disease progression in a patient with metastatic melanoma'. Together they form a unique fingerprint.

Cite this